Oxford PharmaGenesis - generating lifetime pharmaceutical value

Classically, a client needs to find where the product fits in the current treatment algorithm by matching its clinical profile to unmet needs.
At Oxford PharmaGenesis™, we help to find the market fit by:

developing a strategic communication plan covering audiences, objectives and key claims, and coordinating the presentation and publication of preclinical and clinical data
organizing expert Advisory Board meetings to guide research and communication
regulatory submission development, support and risk management planning
raising awareness internally and externally to maximize ongoing investment.

Market access is now an equally important consideration in the prelaunch period; find out how Oxford PharmaGenesis™ can take you beyond market access to patient access.

Once drugs have negotiated the complex regulatory approval process, time is of the essence. In the run-up to launch, we encourage early adoption of novel therapies by:

enthusing the local markets through internal communications
equipping them with core marketing materials to aid communication with healthcare professionals.

A new drug can quickly become old news, but it takes years to become part of established medical practice. Oxford PharmaGenesis™ keeps the message fresh through sustained, consistent communication, which includes:

clear presentation of new findings in the context of existing understanding
innovative use of communication channels
addressing the interests of new audiences in the light of evolving clinical practice
facilitating patient adherence to long-term therapy
building clinical understanding, for example by using epidemiological and burden of illness studies to aid patient management.

Orphan diseases - parenting best practice

There is often little research available to guide the management of rare disorders once effective treatments come to market. This creates special opportunities for industry and academia to work together to develop best practice for patient management. Oxford PharmaGenesis™ helps clients to adopt orphan diseases using tools such as:

patient outcomes surveys
long-term observational studies of patient management
communication of outcomes.

At Oxford PharmaGenesis™, we prefer the term ‘patient access’ to ‘market access’ because the ultimate goal is to enable the right patients to benefit from using your brand. Achieving and maintaining patient access requires successful demonstration of the value of a new brand to all key stakeholders – governments, payers, prescribers and patients – throughout its lifecycle. Oxford PharmaGenesis™ has proven expertise in ensuring that the right messages reach the right audiences through a focused, multidisciplinary approach:

Outcomes research, including design and communication of epidemiological and burden-of-illness studies and validation of patient-reported outcomes tools
Value proposition and message development, including strategic planning and execution of value-based clinical/HE&OR programmes, global value dossiers, country-specific P&R and HTA dossiers and HTA implementation tools
Advocacy development, including stakeholder mapping, policy-maker consensus workshops, and government-level reports
Internal change consultancy (organization/process realignment), including portfolio development and management strategy, sales force optimization, commercialization best practice and development of new selling models.

Find out more about how Oxford PharmaGenesis™ can take you beyond market access to patient access